Analyst consensus rating
Humacyte, Inc. Analyst Consensus Rating
HUMA analyst consensus rating, coverage count and price target evidence.
Direct answer
Humacyte, Inc.'s consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $2.05.
Forecast evidence checked August 9, 2026.
Get free Humacyte, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.72
- Average price target
- $2.05
- High price target
- $4.00
- Low price target
- $1.00
- Target upside
- +185.4%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 9, 2026
- Valid through
- August 16, 2026